Novo Nordisk's position in the glp-1 market may be under threat due to recent clinical wins by Lilly. However, some data suggests Novo Nordisk's products, such as Ozempic, still have support. The companies' relative standings in the market, including the impact of price cuts and potential regulatory developments, are uncertain.